Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal The International Journal of Medical Science and Health Research
Endah Lestari, Endah Lestari
Unknown Affiliation
Dentistry Health Professions Medicine & Pharmacology Nursing Public Health Veterinary

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality Endah Lestari, Endah Lestari; Nur Fitriani, Nur Fitriani
The International Journal of Medical Science and Health Research Vol. 2 No. 5 (2024): The International Journal of Medical Science and Health Research
Publisher : International Medical Journal Corp. Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70070/rkwyyx84

Abstract

Background: The role of 5α-reductase inhibitors (5-ARIs) in managing prostate cancer has been a subject of considerable debate within the medical community. The exploration of these agents has evolved significantly over the years, reflecting both their therapeutic potential and the complexities associated with their use. Literature Review: The reviewed literature presents a multifaceted examination of 5α-reductase inhibitors (5-ARIs) and their implications for prostate cancer management. The introduction establishes a framework for understanding the evolving role of these agents, emphasizing both their potential therapeutic benefits and the concerns that have emerged regarding their use, particularly in relation to prostate cancer risk and mortality. Conclusion: In conclusion, the literature collectively indicates that while 5-ARIs possess therapeutic potential in managing prostate cancer, significant concerns regarding their safety profiles—particularly their association with high-grade tumors and implications for mortality—necessitate a cautious and informed approach in clinical practice. Future research should aim to elucidate the complexities of 5-ARIs, focusing on their integration with existing treatment protocols and the need for individualized patient care.
Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality Endah Lestari, Endah Lestari; Nur Fitriani, Nur Fitriani
The International Journal of Medical Science and Health Research Vol. 2 No. 6 (2024): The International Journal of Medical Science and Health Research
Publisher : International Medical Journal Corp. Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70070/ms7j8w64

Abstract

Background: The role of 5α-reductase inhibitors (5-ARIs) in managing prostate cancer has been a subject of considerable debate within the medical community. The exploration of these agents has evolved significantly over the years, reflecting both their therapeutic potential and the complexities associated with their use. Literature Review: The reviewed literature presents a multifaceted examination of 5α-reductase inhibitors (5-ARIs) and their implications for prostate cancer management. The introduction establishes a framework for understanding the evolving role of these agents, emphasizing both their potential therapeutic benefits and the concerns that have emerged regarding their use, particularly in relation to prostate cancer risk and mortality. Conclusion: In conclusion, the literature collectively indicates that while 5-ARIs possess therapeutic potential in managing prostate cancer, significant concerns regarding their safety profiles—particularly their association with high-grade tumors and implications for mortality—necessitate a cautious and informed approach in clinical practice. Future research should aim to elucidate the complexities of 5-ARIs, focusing on their integration with existing treatment protocols and the need for individualized patient care.
Co-Authors Nur Fitriani, Nur Fitriani